Decoy Therapeutics Inc. (DCOY) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001615219 · SEC filings checked Oct 18, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 12, 2026 | $227,629 | $-2.4M | $-4.46 | Filing |
| Mar 31, 2026 | May 8, 2026 | — | $-2.2M | $-4.18 | Filing |
| Dec 31, 2025 | Mar 31, 2026 | — | $16.1M | $193.99 | Filing |
| Sep 30, 2025 | Nov 14, 2025 | — | $-873,467 | $-1.81 | Filing |
| Jun 30, 2025 | Jul 31, 2025 | $0 | $-957,825 | $-81.21 | Filing |
| Mar 31, 2025 | May 14, 2025 | — | $-1.7M | $-240.07 | Filing |
| Dec 31, 2024 | Jan 17, 2025 | — | $9.7M | $-52.52 | Filing |
| Sep 30, 2024 | Nov 14, 2024 | — | $-972,121 | $-11.38 | Filing |
What would Decoy Therapeutics Inc. have to report for its valuation to change?
At $1.17, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about -77.8% a year, to $0.10. On that path the next quarter needs diluted EPS near $-0.40, against $-1.81 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | -77.8% | -77.8% |
| EPS needed in final year | $0.10 | $0.10 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. DCOY goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.